Application of echinacoside in the preparation of drugs for the prevention or treatment of demyelinating diseases

Echinacea glycoside (ECH) improves myelin structure by promoting oligodendrocyte differentiation and proliferation, thus addressing the limited efficacy of existing treatments for demyelinating diseases. It achieves myelin regeneration and nerve function recovery, significantly improving motor function.

CN122376606APending Publication Date: 2026-07-14CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610546290.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-23
Publication Date
2026-07-14

AI Technical Summary

Technical Problem

Existing treatments for demyelinating diseases have limited efficacy, significant adverse reactions, and cannot effectively promote myelin repair and nerve function recovery. Currently, there are no reports on the role of echinacoside in myelin repair.

Method used

Echinacea glycoside (ECH) was used to promote the differentiation, maturation, and proliferation of oligodendrocytes (OLs), improve myelin ultrastructure, reduce myelin damage, and promote myelin regeneration. Different doses of ECH were administered to mice to treat the disease.

Benefits of technology

It significantly improved the differentiation and proliferation of oligodendrocytes, improved myelin sheath thickness, reduced myelin loss and axonal pathological damage, enhanced nerve conduction function, improved motor coordination and gait function, and provided a new treatment method for demyelinating diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122376606A_ABST
    Figure CN122376606A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of medicine, and particularly relates to application of echinacoside in preparation of a medicine for preventing or treating a demyelination disease; the echinacoside can promote differentiation and maturation of OPCs to OLs, promote proliferation of OLs, promote myelin repair, improve pathological changes of myelin ultrastructure, and promote myelin thickness to return to a normal level; the scheme provides a new treatment means for preventing or treating the demyelination disease, and is expected to reverse disability caused by myelin shedding or damage.
Need to check novelty before this filing date? Find Prior Art